Roustaye Gourabi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roustaye Gourabi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ali Hashemi
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Anita Nikoo
Department of Medical Parasitology and Entomology, Tarbiat Modares University, Tehran, Iran
1 shared publication Bita Khanbabaei
Department of Biological Sciences, Ro.C., Islamic Azad University, Roudehen, Iran
1 shared publication- Javad Yasbolaghi Sharahi
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Masoud Kargar
Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
1 shared publication Mohammad Javad
1 shared publication
Latest Publications
- 18 November 2025
- Published by Springer Nature in Current Microbiology
- Vol. 83 (1) , 25
Cefiderocol: A Comprehensive Review of Chemistry, Mechanisms of Resistance, and Clinical Applications in the Era of Multidrug Resistance
The global spread of multidrug-resistant (MDR) Gram-negative bacteria, particularly carbapenem- and colistin-resistant strains, represents a critical public health crisis with limited therapeutic options. Cefiderocol, a first-in-class siderophore cephalosporin, addresses this challenge through an innovative Trojan horse mechanism. Its unique catechol-containing C-3 side chain enables iron chelation and active transport into bacterial periplasmic space, bypassing traditional resistance pathways. This design confers stability against all Ambler class β-lactamases (A-D), including carbapenemases (blaKPC, blaOXA-48, blaNDM, blaVIM, and blaIMP), and maintains potent activity against MDR Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia. While clinical trials demonstrate efficacy in complicated urinary tract infections, hospital-acquired pneumonia, and bloodstream infections, emerging resistance and mortality signals in specific populations warrant careful consideration. This comprehensive review examines cefiderocol’s molecular structure, mechanisms of action and resistance, pharmacokinetic profile, and clinical applications. We evaluate its position relative to newer β-lactam/β-lactamase inhibitors and explore evidence for combination therapies, ultimately highlighting its crucial role in the antimicrobial arsenal against MDR Gram-negative infections.
- 18 November 2025
- Published by Springer Nature in Current Microbiology
- Vol. 83 (1) , 25
Cefiderocol: A Comprehensive Review of Chemistry, Mechanisms of Resistance, and Clinical Applications in the Era of Multidrug Resistance
The global spread of multidrug-resistant (MDR) Gram-negative bacteria, particularly carbapenem- and colistin-resistant strains, represents a critical public health crisis with limited therapeutic options. Cefiderocol, a first-in-class siderophore cephalosporin, addresses this challenge through an innovative Trojan horse mechanism. Its unique catechol-containing C-3 side chain enables iron chelation and active transport into bacterial periplasmic space, bypassing traditional resistance pathways. This design confers stability against all Ambler class β-lactamases (A-D), including carbapenemases (blaKPC, blaOXA-48, blaNDM, blaVIM, and blaIMP), and maintains potent activity against MDR Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia. While clinical trials demonstrate efficacy in complicated urinary tract infections, hospital-acquired pneumonia, and bloodstream infections, emerging resistance and mortality signals in specific populations warrant careful consideration. This comprehensive review examines cefiderocol’s molecular structure, mechanisms of action and resistance, pharmacokinetic profile, and clinical applications. We evaluate its position relative to newer β-lactam/β-lactamase inhibitors and explore evidence for combination therapies, ultimately highlighting its crucial role in the antimicrobial arsenal against MDR Gram-negative infections.